Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib + Atezolizumab + Paclitaxel in First-line Metastatic TNBC (China cohort of IPATunity130/IMpassion131-like)
CTR20200781Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ipatasertib, atezolizumab, paclitaxel in breast cancer, sponsored by Roche. Started Jul 2020; status: terminated.
02
Drugs
ipatasertibatezolizumabpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20200781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200781.